Skip to content

The short-term impact of intracolonic lidocaine spraying on patients with functional abdominal pain syndrome

The short-term impact of intracolonic lidocaine spraying on patients with functional abdominal pain syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008187
Enrollment
Unknown
Registered
2016-03-30
Start date
2016-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional abdominal pain syndrome

Interventions

experimental group:intracolonic lidocaine spraying
control group:intracolonic saline spraying

Sponsors

Department of Gastroenterology, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18-70 years; 2. no warning symptoms:stool with blood or bloody stool, melena or fecal occult blood test positive, abdominal mass, unexplained weight loss(more than 4.5Kg), iron-deficiency anemia, family history of colorectal cancer, family history of inflammatory bowel disease; 3. meet the Rome III standard for adults with functional abdominal pain syndrome; 4. medical history, physical examination and other examinations found no pathological changes that can explain chronic abdominal pain; 5. willing to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant women and lactating women; 2. Have a history of gastrointestinal or abdominal surgery; 3. painless colonoscopy found pathological changes that can cause abdominal pain: inflammatory bowel disease,intsetinal tumor, stricture of colon, fistula, hemorrhoid,anal fissure, perianal abscess; 4. contraindication of lidocaine: lidocaine allergy,liver and kidney dysfunction,congestive heart-failure, hypotension,cardiac conduction block, Wolff-Parkinson-White syndrome,pulmonary insufficiency; 5. taking drugs that can effect the metabolism of lidocaine,and can not or is not willing to drug withdrawal: Cimetidine, beta-blocker(propranolol, metoprolol), barbiturate(thiopental sodium, phenobarbitone), sodium nitroprusside, mannitol, silvadene, amphotericin B, ampicillin.

Design outcomes

Primary

MeasureTime frame
Degree of abdominal pain;

Secondary

MeasureTime frame
heart rate;bloodpressure;arterial partial pressure of oxygen;

Countries

China

Contacts

Public ContactHu Bing

Department of Gastroenterology, West China Hospital, Sichuan University

hubingnj@163.com+86 18980601278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 16, 2026